학술논문
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Document Type
Article
Author
Stuart, Arabella S V ; Shaw, Robert H ; Liu, Xinxue ; Greenland, Melanie; Aley, Parvinder K; Andrews, Nick J; Cameron, J C; Charlton, Sue; Clutterbuck, Elizabeth A; Collins, Andrea M; Darton, Tom; Dinesh, Tanya; Duncan, Christopher J A; England, Anna; Faust, Saul N; Ferreira, Daniela M; Finn, Adam; Goodman, Anna L; Green, Christopher A; Hallis, Bassam; Heath, Paul T; Hill, Helen; Horsington, Bryn M; Lambe, Teresa; Lazarus, Rajeka; Libri, Vincenzo; Lillie, Patrick J; Mujadidi, Yama F; Payne, Ruth; Plested, Emma L; Provstgaard-Morys, Samuel; Ramasamy, Maheshi N; Ramsay, Mary; Read, Robert C; Robinson, Hannah; Screaton, Gavin R; Singh, Nisha; Turner, David P J; Turner, Paul J; Vichos, Iason; White, Rachel; Nguyen-Van-Tam, Jonathan S; Snape, Matthew D
Source
In The Lancet 1-7 January 2022 399(10319):36-49
Subject
Language
ISSN
0140-6736